RxSight Investors May Pursue Securities Fraud Lawsuit with Deadline Approaching

RxSight investors have an opportunity to lead a securities fraud lawsuit. The class action was filed against the company for allegedly making false and misleading statements and/or failing to disclose challenges, declining sales, and overstated demand for its products. Investors who purchased securities between November 7, 2024 and July 8, 2025, may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement. The lead plaintiff deadline is September 22, 2025.

RxSight, Inc. (NASDAQ: RXST) investors have an opportunity to lead a securities fraud lawsuit against the company. The class action, filed on August 7, 2025, alleges that between November 7, 2024 and July 8, 2025, RxSight made false and misleading statements and/or failed to disclose challenges, declining sales, and overstated demand for its products [1][2][3][4].

The lawsuit, captioned Makaveev v. RxSight, Inc., No. 25-cv-01596 (C.D. Cal.), seeks to represent purchasers or acquirers of RxSight securities who suffered substantial losses. The complaint alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that RxSight was experiencing "adoption challenges" and/or structural issues resulting in declines in sales and utilization, and that defendants had overstated the demand for RxSight’s products [2].

The lawsuit further alleges that on July 8, 2025, RxSight reported significant declines in Light Delivery Device (LDD) sales, LAL utilization, and overall revenue, leading to a nearly 38% drop in the price of RxSight stock [2].

Investors who purchased securities between November 7, 2024 and July 8, 2025, may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement. The deadline to seek to be a lead plaintiff is September 22, 2025 [1][2][3].

The law firms involved in the lawsuit include Robbins Geller Rudman & Dowd LLP, Levi & Korsinsky, LLP, and The Gross Law Firm. These firms have extensive experience in representing investors in complex securities litigation and have secured significant recoveries for investors in the past [1][2][3].

Investors who believe they may be eligible to participate in the lawsuit should contact the law firms involved for more information and to register as a shareholder. There is no cost or obligation to participate in the case [1][2][3].

References:

[1] https://www.morningstar.com/news/globe-newswire/9509304/class-action-filed-against-rxsight-inc-rxst-seeking-recovery-for-investors-contact-levi-korsinsky
[2] https://www.globenewswire.com/news-release/2025/08/07/3129543/0/en/RXST-INVESTOR-ALERT-Robbins-Geller-Rudman-Dowd-LLP-Announces-that-RxSight-Inc-Investors-with-Substantial-Losses-Have-Opportunity-to-Lead-Securities-Class-Action-Lawsuit.html
[3] https://www.globenewswire.com/news-release/2025/08/07/3129789/0/en/Investors-in-RxSight-Inc-Should-Contact-The-Gross-Law-Firm-Before-September-22-2025-to-Discuss-Your-Rights-RXST.html
[4] https://www.marketscreener.com/news/rxsight-inc-rxst-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-ce7c5edad18cf625